BiotechTube

AOC-1020 + Placebo

Phase 3Recruiting
0 views this week 0 watching⚡ Active
Interest: 44/100
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Facioscapulohumeral Muscular Dystrophy

Conditions

Facioscapulohumeral Muscular Dystrophy, FSHD, FSHD - Facioscapulohumeral Muscular Dystrophy, FSHD1, FSHD2, Fascioscapulohumeral Muscular Dystrophy, Fascioscapulohumeral Muscular Dystrophy Type 1, Fascioscapulohumeral Muscular Dystrophy Type 2, Facioscapulohumeral Muscular Dystrophy 1, Facioscapulohumeral Dystrophy, Facio-Scapulo-Humeral Dystrophy, Facioscapulohumeral Muscular Dystrophy 2, Facioscapulohumeral Muscular Dystrophy Type 1 (FSHD1), FSH Muscular Dystrophy, Landouzy Dejerine Dystrophy, Landouzy-Dejerine Muscular Dystrophy, Landouzy-Dejerine Syndrome

Trial Timeline

Jun 10, 2025 → Jul 1, 2028

NCT ID
NCT07038200

About AOC-1020 + Placebo

AOC-1020 + Placebo is a phase 3 stage product being developed by Avidity Biosciences for Facioscapulohumeral Muscular Dystrophy. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07038200. Target conditions include Facioscapulohumeral Muscular Dystrophy, FSHD, FSHD - Facioscapulohumeral Muscular Dystrophy.

What happened to similar drugs?

0 of 1 similar drugs in Facioscapulohumeral Muscular Dystrophy were approved

Approved (0) Terminated (1) Active (0)
❌Losmapimod + Placebo oral tabletFulcrum TherapeuticsPhase 3

Hype Score Breakdown

Clinical
17
Activity
15
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT07038200Phase 3Recruiting

Competing Products

12 competing products in Facioscapulohumeral Muscular Dystrophy

See all competitors
ProductCompanyStageHype Score
ACE-083 + ACE-083 or placeboMerckPhase 2
27
ACE-083MerckPhase 2
27
Placebo + RO7204239RochePhase 2
39
Apitegromab + PlaceboScholar Rock HoldingPhase 2
39
Losmapimod oral tablet + Placebo oral tabletFulcrum TherapeuticsPhase 2
25
Losmapimod + Placebo oral tabletFulcrum TherapeuticsPhase 3
22
LosmapimodFulcrum TherapeuticsPhase 2
17
LosmapimodFulcrum TherapeuticsPhase 2
17
ATYR1940aTyr PharmaPhase 1/2
22
ATYR1940aTyr PharmaPhase 1/2
22
Placebo + ATYR1940aTyr PharmaPhase 1/2
22
ATYR1940aTyr PharmaPhase 1/2
22